ID   LYAG_HUMAN              Reviewed;         952 AA.
AC   P10253; Q09GN4; Q14351; Q16302; Q8IWE7;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   10-MAY-2017, entry version 200.
DE   RecName: Full=Lysosomal alpha-glucosidase;
DE            EC=3.2.1.20;
DE   AltName: Full=Acid maltase;
DE   AltName: Full=Aglucosidase alfa;
DE   Contains:
DE     RecName: Full=76 kDa lysosomal alpha-glucosidase;
DE   Contains:
DE     RecName: Full=70 kDa lysosomal alpha-glucosidase;
DE   Flags: Precursor;
GN   Name=GAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 70-89; 123-145;
RP   204-215; 230-249; 332-345; 349-370; 394-409; 480-513; 520-545;
RP   703-719; 726-731 AND 795-803, AND VARIANTS ARG-199; HIS-223 AND
RP   ILE-780.
RC   TISSUE=Placenta, Testis, and Urine;
RX   PubMed=3049072;
RA   Hoefsloot L.H., Hoogeveen-Westerveld M., Kroos M.A., van Beeumen J.,
RA   Reuser A.J.J., Oostra B.A.;
RT   "Primary structure and processing of lysosomal alpha-glucosidase;
RT   homology with the intestinal sucrase-isomaltase complex.";
RL   EMBO J. 7:1697-1704(1988).
RN   [2]
RP   SEQUENCE REVISION.
RA   Reuser A.J.J.;
RL   Submitted (JUN-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-780.
RX   PubMed=2268276; DOI=10.1042/bj2720493;
RA   Hoefsloot L.H., Hoogeveen-Westerveld M., Reuser A.J.J., Oostra B.A.;
RT   "Characterization of the human lysosomal alpha-glucosidase gene.";
RL   Biochem. J. 272:493-497(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-780.
RX   PubMed=2111708; DOI=10.1089/dna.1990.9.85;
RA   Martiniuk F., Mehler M., Tzall S., Meredith G., Hirschhorn R.;
RT   "Sequence of the cDNA and 5'-flanking region for human acid alpha-
RT   glucosidase, detection of an intron in the 5' untranslated leader
RT   sequence, definition of 18-bp polymorphisms, and differences with
RT   previous cDNA and amino acid sequences.";
RL   DNA Cell Biol. 9:85-94(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT GSD2 LEU-457, AND VARIANTS
RP   ARG-199; HIS-223 AND ILE-780.
RA   Ghaffari S.R., Sabokbar T., Tahmasebi S., Dastan J.;
RT   "Identification of a novel mutation in the acid alpha glucosidase gene
RT   causing juvenile form of Pompe disease in Iranian population.";
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 631-680, AND VARIANT GSD2 HIS-645.
RX   PubMed=7695647; DOI=10.1006/bbrc.1995.1418;
RA   Lin C.-Y., Shieh J.-J.;
RT   "Identification of a de novo point mutation resulting in infantile
RT   form of Pompe's disease.";
RL   Biochem. Biophys. Res. Commun. 208:886-893(1995).
RN   [9]
RP   MUTAGENESIS OF TRP-516 AND ASP-518, AND ACTIVE SITE.
RX   PubMed=1856189;
RA   Hermans M.M.P., Kroos M.A., van Beeumen J., Oostra B.A.,
RA   Reuser A.J.J.;
RT   "Human lysosomal alpha-glucosidase. Characterization of the catalytic
RT   site.";
RL   J. Biol. Chem. 266:13507-13512(1991).
RN   [10]
RP   GLYCOSYLATION AT ASN-140; ASN-233; ASN-390; ASN-470; ASN-652; ASN-882
RP   AND ASN-925.
RX   PubMed=8435067; DOI=10.1042/bj2890681;
RA   Hermans M.M.P., Wisselaar H.A., Kroos M.A., Oostra B.A.,
RA   Reuser A.J.J.;
RT   "Human lysosomal alpha-glucosidase: functional characterization of the
RT   glycosylation sites.";
RL   Biochem. J. 289:681-686(1993).
RN   [11]
RP   GLYCOSYLATION AT ASN-470.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [12]
RP   REVIEW ON VARIANTS.
RX   PubMed=7603530; DOI=10.1002/mus.880181414;
RA   Reuser A.J.J., Kroos M.A., Hermans M.M.P., Bijvoet A.G.A.,
RA   Verbeet M.P., van Diggelen O.P., Kleijer W.J., van der Ploeg A.T.;
RT   "Glycogenosis type II (acid maltase deficiency).";
RL   Muscle Nerve 3:S61-S69(1995).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-390.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-140; ASN-470; ASN-882 AND
RP   ASN-925.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [19]
RP   VARIANT ASN-91.
RX   PubMed=2203258;
RA   Martiniuk F., Bodkin M., Tzall S., Hirschhorn R.;
RT   "Identification of the base-pair substitution responsible for a human
RT   acid alpha glucosidase allele with lower 'affinity' for glycogen (GAA
RT   2) and transient gene expression in deficient cells.";
RL   Am. J. Hum. Genet. 47:440-445(1990).
RN   [20]
RP   VARIANT GSD2 THR-318.
RX   PubMed=1652892;
RA   Zhong N., Martiniuk F., Tzall S., Hirschhorn R.;
RT   "Identification of a missense mutation in one allele of a patient with
RT   Pompe disease, and use of endonuclease digestion of PCR-amplified RNA
RT   to demonstrate lack of mRNA expression from the second allele.";
RL   Am. J. Hum. Genet. 49:635-645(1991).
RN   [21]
RP   VARIANT GSD2 LYS-521.
RX   PubMed=1898413; DOI=10.1016/0006-291X(91)91906-S;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Wisselaar H.A., Oostra B.A.,
RA   Reuser A.J.J.;
RT   "Identification of a point mutation in the human lysosomal alpha-
RT   glucosidase gene causing infantile glycogenosis type II.";
RL   Biochem. Biophys. Res. Commun. 179:919-926(1991).
RN   [22]
RP   VARIANTS GSD2 ARG-643 AND TRP-725.
RX   PubMed=8401535; DOI=10.1002/humu.1380020406;
RA   Hermans M.M.P., Kroos M.A., de Graaff E., Oostra B.A., Reuser A.J.J.;
RT   "Two mutations affecting the transport and maturation of lysosomal
RT   alpha-glucosidase in an adult case of glycogen storage disease type
RT   II.";
RL   Hum. Mutat. 2:268-273(1993).
RN   [23]
RP   VARIANT GSD2 GLU-645, AND VARIANTS ILE-816 AND ILE-927.
RX   PubMed=8094613; DOI=10.1042/bj2890687;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Wisselaar H.A.,
RA   Willemsen R., Oostra B.A., Reuser A.J.J.;
RT   "The conservative substitution Asp-645-->Glu in lysosomal alpha-
RT   glucosidase affects transport and phosphorylation of the enzyme in an
RT   adult patient with glycogen-storage disease type II.";
RL   Biochem. J. 289:687-693(1993).
RN   [24]
RP   VARIANT GSD2 GLU-645, AND VARIANTS ILE-816 AND ILE-927.
RX   PubMed=1684505; DOI=10.1089/dna.1991.10.681;
RA   Martiniuk F., Mehler M., Bodkin M., Tzall S., Hirschhorn K., Zhong N.,
RA   Hirschhorn R.;
RT   "Identification of a missense mutation in an adult-onset patient with
RT   glycogenosis type II expressing only one allele.";
RL   DNA Cell Biol. 10:681-687(1991).
RN   [25]
RP   VARIANTS ILE-816 AND ILE-927.
RX   PubMed=8486380; DOI=10.1006/geno.1993.1185;
RA   Hermans M.M.P., Svetkey L.P., Oostra B.A., Chen Y.T., Reuser A.J.J.;
RT   "The loss of a polymorphic glycosylation site caused by Thr-927-->Ile
RT   is linked to a second polymorphic Val-816-->Ile substitution in
RT   lysosomal alpha-glucosidase of American blacks.";
RL   Genomics 16:300-301(1993).
RN   [26]
RP   VARIANT GSD2 VAL-519.
RX   PubMed=7866409; DOI=10.1002/humu.1380040410;
RA   Huie M.L., Hirschhorn R., Chen A.S., Martiniuk F., Zhong N.;
RT   "Mutation at the catalytic site (M519V) in glycogen storage disease
RT   type II (Pompe disease).";
RL   Hum. Mutat. 4:291-293(1994).
RN   [27]
RP   VARIANT GSD2 TRP-647.
RX   PubMed=7981676; DOI=10.1093/hmg/3.7.1081;
RA   Huie M.L., Chen A.S., Brooks S.S., Grix A., Hirschhorn R.;
RT   "A de novo 13 nt deletion, a newly identified C647W missense mutation
RT   and a deletion of exon 18 in infantile onset glycogen storage disease
RT   type II (GSDII).";
RL   Hum. Mol. Genet. 3:1081-1087(1994).
RN   [28]
RP   VARIANT GSD2 LEU-545.
RX   PubMed=7881422; DOI=10.1093/hmg/3.12.2213;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Mohkamsing S., Eussen B.J.,
RA   Joosse M., Willemsen R., Kleijer W.J., Oostra B.A., Reuser A.J.J.;
RT   "The effect of a single base pair deletion (delta T525) and a C1634T
RT   missense mutation (Pro545Leu) on the expression of lysosomal alpha-
RT   glucosidase in patients with glycogen storage disease type II.";
RL   Hum. Mol. Genet. 3:2213-2218(1994).
RN   [29]
RP   VARIANTS GSD2 ARG-299 AND LYS-903 DEL, AND VARIANTS ARG-199; HIS-223
RP   AND ILE-780.
RX   PubMed=7717400;
RA   Boerkoel C.F., Exelbert R., Nicastri C., Nichols R.C., Miller F.W.,
RA   Plotz P.H., Raben N.;
RT   "Leaky splicing mutation in the acid maltase gene is associated with
RT   delayed onset of glycogenosis type II.";
RL   Am. J. Hum. Genet. 56:887-897(1995).
RN   [30]
RP   VARIANT LYS-689.
RX   PubMed=8912788; DOI=10.1111/j.1469-1809.1996.tb00433.x;
RA   Huie M.L., Menaker M., McAlpine P.J., Hirschhorn R.;
RT   "Identification of an E689K substitution as the molecular basis of the
RT   human acid alpha-glucosidase type 4 allozyme (GAA*4).";
RL   Ann. Hum. Genet. 60:365-368(1996).
RN   [31]
RP   VARIANT GSD2 VAL-529.
RX   PubMed=8834250; DOI=10.1007/BF02267074;
RA   Tsunoda H., Ohshima T., Tohyama J., Sasaki M., Sakuragawa N.,
RA   Martiniuk F.;
RT   "Acid alpha-glucosidase deficiency: identification and expression of a
RT   missense mutation (S529V) in a Japanese adult phenotype.";
RL   Hum. Genet. 97:496-499(1996).
RN   [32]
RP   VARIANTS GSD2 ASN-645; TRP-647; SER-648; GLN-672 AND TRP-672.
RX   PubMed=9535769; DOI=10.1006/bbrc.1998.8255;
RA   Huie M.L., Tsujino S., Brooks S.S., Engel A., Elias E., Bonthron D.T.,
RA   Bessley C., Shanske S., Dimauro S., Goto Y., Hirschhorn R.;
RT   "Glycogen storage disease type II: identification of four novel
RT   missense mutations (D645N, G648S, R672W, R672Q) and two
RT   insertions/deletions in the acid alpha-glucosidase locus of patients
RT   of differing phenotype.";
RL   Biochem. Biophys. Res. Commun. 244:921-927(1998).
RN   [33]
RP   VARIANT GSD2 ARG-309.
RX   PubMed=9660056;
RA   Kroos M.A., van Leenen D., Verbiest J., Reuser A.J.J., Hermans M.M.P.;
RT   "Glycogen storage disease type II: identification of a dinucleotide
RT   deletion and a common missense mutation in the lysosomal alpha-
RT   glucosidase gene.";
RL   Clin. Genet. 53:379-382(1998).
RN   [34]
RP   VARIANTS GSD2 PRO-566; ARG-643 AND ARG-768, AND VARIANTS ASN-91;
RP   ARG-199 AND HIS-223.
RX   PubMed=9521422;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:3<209::AID-HUMU5>3.3.CO;2-R;
RA   Hermans M.M.P., Kroos M.A., Smeitink J.A.M., van der Ploeg A.T.,
RA   Kleijer W.J., Reuser A.J.J.;
RT   "Glycogen storage disease type II: genetic and biochemical analysis of
RT   novel mutations in infantile patients from Turkish ancestry.";
RL   Hum. Mutat. 11:209-215(1998).
RN   [35]
RP   VARIANT GSD2 GLY-VAL-PRO-VAL-SER-ASN-925 INS.
RX   PubMed=10206684;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<413::AID-HUMU16>3.0.CO;2-I;
RA   Beesley C.E., Child A.H., Yacoub M.Y.;
RT   "The identification of five novel mutations in the lysosomal acid
RT   alpha-(1,4) glucosidase gene from patients with glycogen storage
RT   disease type II.";
RL   Hum. Mutat. 11:413-413(1998).
RN   [36]
RP   VARIANTS GSD2 LEU-545 AND TRP-638.
RX   PubMed=10737124; DOI=10.1007/s100480050030;
RA   Vorgerd M., Burwinkel B., Reichmann H., Malin J.-P., Kilimann M.W.;
RT   "Adult-onset glycogen storage disease type II: phenotypic and allelic
RT   heterogeneity in German patients.";
RL   Neurogenetics 1:205-211(1998).
RN   [37]
RP   VARIANT GSD2 ARG-481.
RX   PubMed=10189220;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:1<83::AID-HUMU13>3.0.CO;2-2;
RA   Raben N., Lee E., Lee L., Hirschhorn R., Plotz P.H.;
RT   "Novel mutations in African American patients with glycogen storage
RT   disease Type II.";
RL   Hum. Mutat. 13:83-84(1999).
RN   [38]
RP   VARIANTS GSD2, AND VARIANTS.
RX   PubMed=10338092;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<380::AID-HUMU6>3.0.CO;2-A;
RA   Ko T.-M., Hwu W.-L., Lin Y.-W., Tseng L.-H., Hwa H.-L., Wang T.-R.,
RA   Chuang S.-M.;
RT   "Molecular genetic study of Pompe disease in Chinese patients in
RT   Taiwan.";
RL   Hum. Mutat. 13:380-384(1999).
RN   [39]
RP   VARIANTS GSD2 PRO-208; LEU-308; LEU-324; MET-585; 607-GLY--HIS-612
RP   DEL; ARG-643 AND THR-672.
RX   PubMed=11071489; DOI=10.1212/WNL.55.8.1122;
RA   Laforet P., Nicolino M., Eymard P.B., Puech J.P., Caillaud C.,
RA   Poenaru L., Fardeau M.;
RT   "Juvenile and adult-onset acid maltase deficiency in France: genotype-
RT   phenotype correlation.";
RL   Neurology 55:1122-1128(2000).
RN   [40]
RP   VARIANTS GSD2 ARG-219; LYS-262 AND VAL-408.
RX   PubMed=11738358; DOI=10.1016/S0960-8966(01)00247-4;
RA   Fernandez-Hojas R., Huie M.L., Navarro C., Dominguez C., Roig M.,
RA   Lopez-Coronas D., Teijeira S., Anyane-Yeboa K., Hirschhorn R.;
RT   "Identification of six novel mutations in the acid alpha-glucosidase
RT   gene in three Spanish patients with infantile onset glycogen storage
RT   disease type II (Pompe disease).";
RL   Neuromuscul. Disord. 12:159-166(2002).
RN   [41]
RP   VARIANT GSD2 TRP-224, AND CHARACTERIZATION OF VARIANT GSD2 TRP-224.
RX   PubMed=12923862; DOI=10.1002/ajmg.a.20164;
RA   Pittis M.G., Montalvo A.L., Miocic S., Martini C., Deganuto M.,
RA   Candusso M., Ciana G., Bembi B.;
RT   "Identification of four novel mutations in the alpha glucosidase gene
RT   in five Italian patients with infantile onset glycogen storage disease
RT   type II.";
RL   Am. J. Med. Genet. A 121:225-230(2003).
RN   [42]
RP   VARIANTS GSD2 LEU-361 AND CYS-437.
RX   PubMed=12601120; DOI=10.1212/01.WNL.0000048661.95327.BF;
RA   Lam C.W., Yuen Y.P., Chan K.Y., Tong S.F., Lai C.K., Chow T.C.,
RA   Lee K.C., Chan Y.W., Martiniuk F.;
RT   "Juvenile-onset glycogen storage disease type II with novel mutations
RT   in acid alpha-glucosidase gene.";
RL   Neurology 60:715-717(2003).
RN   [43]
RP   VARIANTS GSD2 TRP-224; CYS-600; ARG-619 AND HIS-660, CHARACTERIZATION
RP   OF VARIANTS GSD2 TRP-224; ARG-619 AND HIS-660, AND CHARACTERIZATION OF
RP   VARIANT SER-576.
RX   PubMed=14643388; DOI=10.1016/S0887-8994(03)00267-4;
RA   Pipo J.R., Feng J.-H., Yamamoto T., Ohsaki Y., Nanba E., Tsujino S.,
RA   Sakuragawa N., Martiniuk F., Ninomiya H., Oka A., Ohno K.;
RT   "New GAA mutations in Japanese patients with GSDII (Pompe disease).";
RL   Pediatr. Neurol. 29:284-287(2003).
RN   [44]
RP   VARIANTS GSD2 GLY-103; ARG-219; ARG-285; CYS-292; ARG-293; PRO-308;
RP   ARG-312; PRO-355; ARG-374; PRO-405; PHE-455; ASP-459 DEL; ARG-478;
RP   ARG-481; THR-519; LEU-545; ARG-549; PRO-552; SER-575; LYS-579;
RP   CYS-600; ASP-607 AND ASP-880, AND CHARACTERIZATION OF VARIANTS.
RX   PubMed=14695532; DOI=10.1002/humu.10286;
RA   Hermans M.M.P., van Leenen D., Kroos M.A., Beesley C.E.,
RA   Van der Ploeg A.T., Sakuraba H., Wevers R., Kleijer W.J.,
RA   Michelakakis H., Kirk E.P., Fletcher J., Bosshard N.,
RA   Basel-Vanagaite L., Besley G., Reuser A.J.J.;
RT   "Twenty-two novel mutations in the lysosomal alpha-glucosidase gene
RT   (GAA) underscore the genotype-phenotype correlation in glycogen
RT   storage disease type II.";
RL   Hum. Mutat. 23:47-56(2004).
RN   [45]
RP   VARIANTS GSD2 PRO-355 AND CYS-702, AND CHARACTERIZATION OF VARIANTS
RP   GSD2 PRO-355 AND CYS-702.
RX   PubMed=14972326; DOI=10.1016/j.ymgme.2003.11.011;
RA   Montalvo A.L.E., Cariati R., Deganuto M., Guerci V., Garcia R.,
RA   Ciana G., Bembi B., Pittis M.G.;
RT   "Glycogenosis type II: identification and expression of three novel
RT   mutations in the acid alpha-glucosidase gene causing the infantile
RT   form of the disease.";
RL   Mol. Genet. Metab. 81:203-208(2004).
RN   [46]
RP   VARIANT GSD2 GLN-901, AND VARIANT ASN-645.
RX   PubMed=15145338; DOI=10.1016/j.nmd.2004.02.012;
RA   Kroos M.A., Kirschner J., Gellerich F.N., Hermans M.M.,
RA   Van der Ploeg A.T., Reuser A.J., Korinthenberg R.;
RT   "A case of childhood Pompe disease demonstrating phenotypic
RT   variability of p.Asp645Asn.";
RL   Neuromuscul. Disord. 14:371-374(2004).
RN   [47]
RP   VARIANTS GSD2 VAL-237 AND ARG-293.
RX   PubMed=15668445; DOI=10.1212/01.WNL.0000149528.95362.20;
RA   Anneser J.M., Pongratz D.E., Podskarbi T., Shin Y.S., Schoser B.G.;
RT   "Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient
RT   with an unusual phenotype.";
RL   Neurology 64:368-370(2005).
RN   [48]
RP   VARIANT GSD2 GLY-330.
RX   PubMed=16782080; DOI=10.1016/j.cca.2006.04.007;
RA   Dou W., Gu X., Fu L., Peng C., Zheng J., Martiniuk F., Sheng H.Z.;
RT   "A novel missense mutation in the acid alpha-glucosidase gene causing
RT   the classic infantile form of Pompe disease.";
RL   Clin. Chim. Acta 374:145-146(2006).
RN   [49]
RP   VARIANT GSD2 GLY-ASN-404.
RX   PubMed=16433701; DOI=10.1111/j.1399-0004.2005.00557.x;
RA   Amartino H., Painceira D., Pomponio R.J., Niizawa G., Sabio Paz V.,
RA   Blanco M., Chamoles N.;
RT   "Two clinical forms of glycogen-storage disease type II in two
RT   generations of the same family.";
RL   Clin. Genet. 69:187-188(2006).
RN   [50]
RP   VARIANTS GSD2 ARG-309; PRO-355; LEU-361; PRO-445; ASN-489; ARG-549;
RP   GLN-612; ARG-643; TRP-672 AND CYS-746.
RX   PubMed=16917947; DOI=10.1002/humu.20374;
RA   Montalvo A.L., Bembi B., Donnarumma M., Filocamo M., Parenti G.,
RA   Rossi M., Merlini L., Buratti E., De Filippi P., Dardis A.,
RA   Stroppiano M., Ciana G., Pittis M.G.;
RT   "Mutation profile of the GAA gene in 40 Italian patients with late
RT   onset glycogen storage disease type II.";
RL   Hum. Mutat. 27:999-1006(2006).
RN   [51]
RP   VARIANTS GSD2 PRO-355; ALA-522 AND VAL-610, AND VARIANT ARG-359.
RX   PubMed=17643989; DOI=10.1016/j.nmd.2007.06.002;
RA   Muller-Felber W., Horvath R., Gempel K., Podskarbi T., Shin Y.,
RA   Pongratz D., Walter M.C., Baethmann M., Schlotter-Weigel B.,
RA   Lochmuller H., Schoser B.;
RT   "Late onset Pompe disease: clinical and neurophysiological spectrum of
RT   38 patients including long-term follow-up in 18 patients.";
RL   Neuromuscul. Disord. 17:698-706(2007).
RN   [52]
RP   VARIANTS GSD2 HIS-190; SER-285; PHE-291; PRO-291; LYS-318; ARG-335;
RP   ARG-347; ARG-482; VAL-483; GLN-521; SER-522; LYS-570; GLN-572;
RP   PRO-594; LYS-614; ASN-737; SER-746 AND PRO-935, AND VARIANT LYS-585.
RX   PubMed=18425781; DOI=10.1002/humu.20745;
RA   Kroos M., Pomponio R.J., van Vliet L., Palmer R.E., Phipps M.,
RA   Van der Helm R., Halley D., Reuser A.;
RT   "Update of the Pompe disease mutation database with 107 sequence
RT   variants and a format for severity rating.";
RL   Hum. Mutat. 29:E13-E26(2008).
RN   [53]
RP   VARIANTS GSD2 GLY-103; CYS-191; ARG-219; TRP-224; LYS-262; ARG-293;
RP   PRO-355; LEU-375; ARG-401; ASN-489; ALA-522; PRO-552; TYR-599;
RP   TRP-638; ARG-643 AND ASN-645, AND CHARACTERIZATION OF VARIANTS GSD2
RP   CYS-191; LEU-375; ARG-401; ALA-522 AND TYR-599.
RX   PubMed=18429042; DOI=10.1002/humu.20753;
RA   Pittis M.G., Donnarumma M., Montalvo A.L.E., Dominissini S., Kroos M.,
RA   Rosano C., Stroppiano M., Bianco M.G., Donati M.A., Parenti G.,
RA   D'Amico A., Ciana G., Di Rocco M., Reuser A., Bembi B., Filocamo M.;
RT   "Molecular and functional characterization of eight novel GAA
RT   mutations in Italian infants with Pompe disease.";
RL   Hum. Mutat. 29:E27-E36(2008).
RN   [54]
RP   VARIANTS GSD2 PRO-46; LEU-217; PRO-486; PRO-594; TYR-612; LYS-635 AND
RP   VAL-638.
RX   PubMed=19588081; DOI=10.1007/s00415-009-5219-y;
RA   Oba-Shinjo S.M., da Silva R., Andrade F.G., Palmer R.E.,
RA   Pomponio R.J., Ciociola K.M., Carvalho S.M., Gutierrez P.S., Porta G.,
RA   Marrone C.D., Munoz V., Grzesiuk A.K., Llerena J.C. Jr.,
RA   Berditchevsky C.R., Sobreira C., Horovitz D., Hatem T.P., Frota E.R.,
RA   Pecchini R., Kouyoumdjian J.A., Werneck L., Amado V.M.,
RA   Camelo J.S. Jr., Mattaliano R.J., Marie S.K.;
RT   "Pompe disease in a Brazilian series: clinical and molecular analyses
RT   with identification of nine new mutations.";
RL   J. Neurol. 256:1881-1890(2009).
RN   [55]
RP   VARIANT GSD2 SER-558.
RX   PubMed=20350966; DOI=10.1177/0883073809356035;
RA   Alcantara-Ortigoza M.A., Gonzalez-del Angel A., Barrientos-Rios R.,
RA   Cupples C., Garrido-Garcia L.M., de Leon-Bojorge B.,
RA   Alva-Chaire Adel C.;
RT   "Screening of late-onset Pompe disease in a sample of Mexican patients
RT   with myopathies of unknown etiology: identification of a novel
RT   mutation in the acid alpha-glucosidase gene.";
RL   J. Child Neurol. 25:1034-1037(2010).
RN   [56]
RP   VARIANTS GSD2 PRO-224; LEU-251; LEU-254; LYS-262; SER-266; PRO-291;
RP   VAL-408; ARG-478; TYR-525; LEU-545; PHE-557; ARG-615; GLU-645; GLY-746
RP   AND CYS-746, AND VARIANTS ALA-271 AND ARG-711.
RX   PubMed=20080426; DOI=10.1016/j.ymgme.2009.12.014;
RA   Labrousse P., Chien Y.H., Pomponio R.J., Keutzer J., Lee N.C.,
RA   Akmaev V.R., Scholl T., Hwu W.L.;
RT   "Genetic heterozygosity and pseudodeficiency in the Pompe disease
RT   newborn screening pilot program.";
RL   Mol. Genet. Metab. 99:379-383(2010).
RN   [57]
RP   VARIANT GSD2 GLY-103, AND VARIANT ASN-91.
RX   PubMed=21109266; DOI=10.1016/j.jns.2010.10.031;
RA   Fidzianska A., Lugowska A., Tylki-Szymanska A.;
RT   "Late form of Pompe disease with glycogen storage in peripheral nerves
RT   axons.";
RL   J. Neurol. Sci. 301:59-62(2011).
RN   [58]
RP   VARIANTS HIS-74; HIS-89; LEU-220; MET-222; ASP-290; GLY-310; VAL-391;
RP   CYS-458; ASP-611; LEU-629; 700-THR-LEU-701 DEL AND ILE-718, AND
RP   VARIANTS GSD2 ARG-103; GLY-108; PHE-127; GLN-224; ARG-234; LYS-234;
RP   ILE-316; GLU-335; LEU-361; LEU-397; VAL-419; HIS-457; TYR-523;
RP   SER-558; CYS-575; ARG-576; HIS-594; LEU-601; ALA-602; PRO-627;
RP   ASP-648; LEU-702; LYS-743; PRO-819 AND PHE-916.
RX   PubMed=22644586; DOI=10.1002/humu.22108;
RA   Kroos M., Hoogeveen-Westerveld M., Michelakakis H., Pomponio R.,
RA   Van der Ploeg A., Halley D., Reuser A., Augoustides-Savvopoulou P.,
RA   Ausems M., Llona J.B., Bautista Lorite J., van der Beek N., Bonafe L.,
RA   Cuk M., D'Hooghe M., Engelen B., Farouk A., Fumic K.,
RA   Garcia-Delgado E., Herzog A., Hurst J., Jones S., Kariminejad M.H.,
RA   Kucukcongar A., Lissens W., Lund A., Majoor-Krakauer D., Kumamoto S.,
RA   Maravi E., Marie S., Mengel E., Mavridou I., Munteis Olivas E.,
RA   Najmabadi H., Okumiya T., Peric S., Paschke E., Plecko B.,
RA   Robberecht W., Serdaroglu P., Shboul M., Tansek M.Z., Tarnutzer A.,
RA   Stojanovic V.R., Tylki-Szymanska A., Venancio M., Verhoeven K.;
RT   "Update of the pompe disease mutation database with 60 novel GAA
RT   sequence variants and additional studies on the functional effect of
RT   34 previously reported variants.";
RL   Hum. Mutat. 33:1161-1165(2012).
RN   [59]
RP   VARIANTS GSD2 LYS-234; 431-LEU--GLN-433 DEL; LEU-568; LEU-601; CYS-766
RP   AND ARG-913.
RX   PubMed=22676651; DOI=10.1186/1750-1172-7-35;
RA   Herzog A., Hartung R., Reuser A.J., Hermanns P., Runz H., Karabul N.,
RA   Goekce S., Pohlenz J., Kampmann C., Lampe C., Beck M., Mengel E.;
RT   "A cross-sectional single-centre study on the spectrum of Pompe
RT   disease, German patients: molecular analysis of the GAA gene,
RT   manifestation and genotype-phenotype correlations.";
RL   Orphanet J. Rare Dis. 7:35-35(2012).
RN   [60]
RP   VARIANTS GSD2 VAL-391; HIS-437; PRO-552; ASP-611; VAL-641; TRP-647 AND
RP   PRO-705, AND VARIANTS ASN-91; ARG-199; HIS-223; SER-576; LYS-689;
RP   ILE-780 AND ILE-816.
RX   PubMed=25681614; DOI=10.1016/j.gene.2015.02.023;
RA   Turaca L.T., de Faria D.O., Kyosen S.O., Teixeira V.D., Motta F.L.,
RA   Pessoa J.G., Rodrigues E Silva M., de Almeida S.S., D'Almeida V.,
RA   Munoz Rojas M.V., Martins A.M., Pesquero J.B.;
RT   "Novel GAA mutations in patients with Pompe disease.";
RL   Gene 561:124-131(2015).
CC   -!- FUNCTION: Essential for the degradation of glygogen to glucose in
CC       lysosomes.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal, non-reducing (1->4)-
CC       linked alpha-D-glucose residues with release of alpha-D-glucose.
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:17897319}.
CC       Lysosome membrane {ECO:0000269|PubMed:17897319}.
CC   -!- PTM: The different forms of acid glucosidase are obtained by
CC       proteolytic processing.
CC   -!- PTM: Phosphorylation of mannose residues ensures efficient
CC       transport of the enzyme to the lysosomes via the mannose 6-
CC       phosphate receptor.
CC   -!- POLYMORPHISM: There are three common alleles of GAA: GAA*1, GAA*2
CC       and GAA*4. The sequence shown is that of allele GAA*1, which is
CC       the most common. Alleles GAA*2 and GAA*4 are much rarer.
CC       {ECO:0000269|PubMed:21109266, ECO:0000269|PubMed:2203258,
CC       ECO:0000269|PubMed:25681614, ECO:0000269|PubMed:8912788,
CC       ECO:0000269|PubMed:9521422}.
CC   -!- DISEASE: Glycogen storage disease 2 (GSD2) [MIM:232300]: A
CC       metabolic disorder with a broad clinical spectrum. The severe
CC       infantile form, or Pompe disease, presents at birth with massive
CC       accumulation of glycogen in muscle, heart and liver.
CC       Cardiomyopathy and muscular hypotonia are the cardinal features of
CC       this form whose life expectancy is less than two years. The
CC       juvenile and adult forms present as limb-girdle muscular dystrophy
CC       beginning in the lower limbs. Final outcome depends on respiratory
CC       muscle failure. Patients with the adult form can be free of
CC       clinical symptoms for most of their life but finally develop a
CC       slowly progressive myopathy. {ECO:0000269|PubMed:10189220,
CC       ECO:0000269|PubMed:10206684, ECO:0000269|PubMed:10338092,
CC       ECO:0000269|PubMed:10737124, ECO:0000269|PubMed:11071489,
CC       ECO:0000269|PubMed:11738358, ECO:0000269|PubMed:12601120,
CC       ECO:0000269|PubMed:12923862, ECO:0000269|PubMed:14643388,
CC       ECO:0000269|PubMed:14695532, ECO:0000269|PubMed:14972326,
CC       ECO:0000269|PubMed:15145338, ECO:0000269|PubMed:15668445,
CC       ECO:0000269|PubMed:16433701, ECO:0000269|PubMed:1652892,
CC       ECO:0000269|PubMed:16782080, ECO:0000269|PubMed:1684505,
CC       ECO:0000269|PubMed:16917947, ECO:0000269|PubMed:17643989,
CC       ECO:0000269|PubMed:18425781, ECO:0000269|PubMed:18429042,
CC       ECO:0000269|PubMed:1898413, ECO:0000269|PubMed:19588081,
CC       ECO:0000269|PubMed:20080426, ECO:0000269|PubMed:20350966,
CC       ECO:0000269|PubMed:21109266, ECO:0000269|PubMed:22644586,
CC       ECO:0000269|PubMed:22676651, ECO:0000269|PubMed:25681614,
CC       ECO:0000269|PubMed:7695647, ECO:0000269|PubMed:7717400,
CC       ECO:0000269|PubMed:7866409, ECO:0000269|PubMed:7881422,
CC       ECO:0000269|PubMed:7981676, ECO:0000269|PubMed:8094613,
CC       ECO:0000269|PubMed:8401535, ECO:0000269|PubMed:8834250,
CC       ECO:0000269|PubMed:9521422, ECO:0000269|PubMed:9535769,
CC       ECO:0000269|PubMed:9660056, ECO:0000269|Ref.5}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 31 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=GAA; Note=Mutations in alpha-glucosidase;
CC       URL="http://cluster15.erasmusmc.nl/klgn/pompe/mutations.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-glucosidase entry;
CC       URL="https://en.wikipedia.org/wiki/Alpha-glucosidase";
CC   -!- WEB RESOURCE: Name=Glucosidase, alpha, acid (Pompe disease) (GAA);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/GAA";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00839; CAA68763.1; -; mRNA.
DR   EMBL; Y00839; CAA68764.1; -; mRNA.
DR   EMBL; X55080; CAC12967.1; -; Genomic_DNA.
DR   EMBL; X55081; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55095; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55082; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55084; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55083; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55098; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55085; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55086; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55087; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55088; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55089; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55090; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55096; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55091; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55092; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55093; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55094; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55097; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; M34424; AAA52506.1; -; mRNA.
DR   EMBL; DQ907243; ABI53718.1; -; mRNA.
DR   EMBL; AC087741; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC040431; AAH40431.1; -; mRNA.
DR   EMBL; S76893; AAB33842.1; -; mRNA.
DR   CCDS; CCDS32760.1; -.
DR   PIR; A40577; A32609.
DR   RefSeq; NP_000143.2; NM_000152.4.
DR   RefSeq; NP_001073271.1; NM_001079803.2.
DR   RefSeq; NP_001073272.1; NM_001079804.2.
DR   RefSeq; XP_005257250.1; XM_005257193.2.
DR   RefSeq; XP_005257251.1; XM_005257194.4.
DR   UniGene; Hs.1437; -.
DR   UniGene; Hs.733627; -.
DR   ProteinModelPortal; P10253; -.
DR   SMR; P10253; -.
DR   BioGrid; 108823; 43.
DR   IntAct; P10253; 8.
DR   STRING; 9606.ENSP00000305692; -.
DR   BindingDB; P10253; -.
DR   ChEMBL; CHEMBL2608; -.
DR   DrugBank; DB00284; Acarbose.
DR   DrugBank; DB05200; AT2220.
DR   DrugBank; DB00491; Miglitol.
DR   GuidetoPHARMACOLOGY; 2611; -.
DR   Allergome; 9614; Hom s Glucosidase.
DR   CAZy; GH31; Glycoside Hydrolase Family 31.
DR   iPTMnet; P10253; -.
DR   PhosphoSitePlus; P10253; -.
DR   UniCarbKB; P10253; -.
DR   BioMuta; GAA; -.
DR   DMDM; 317373572; -.
DR   EPD; P10253; -.
DR   MaxQB; P10253; -.
DR   PaxDb; P10253; -.
DR   PeptideAtlas; P10253; -.
DR   PRIDE; P10253; -.
DR   DNASU; 2548; -.
DR   Ensembl; ENST00000302262; ENSP00000305692; ENSG00000171298.
DR   Ensembl; ENST00000390015; ENSP00000374665; ENSG00000171298.
DR   GeneID; 2548; -.
DR   KEGG; hsa:2548; -.
DR   UCSC; uc002jxo.4; human.
DR   CTD; 2548; -.
DR   DisGeNET; 2548; -.
DR   GeneCards; GAA; -.
DR   GeneReviews; GAA; -.
DR   HGNC; HGNC:4065; GAA.
DR   HPA; HPA026970; -.
DR   HPA; HPA029126; -.
DR   MalaCards; GAA; -.
DR   MIM; 232300; phenotype.
DR   MIM; 606800; gene.
DR   neXtProt; NX_P10253; -.
DR   OpenTargets; ENSG00000171298; -.
DR   Orphanet; 308604; Glycogen storage disease due to acid maltase deficiency, adult onset.
DR   Orphanet; 308552; Glycogen storage disease due to acid maltase deficiency, infantile onset.
DR   Orphanet; 308573; Glycogen storage disease due to acid maltase deficiency, juvenile onset.
DR   PharmGKB; PA28476; -.
DR   eggNOG; KOG1065; Eukaryota.
DR   eggNOG; COG1501; LUCA.
DR   GeneTree; ENSGT00760000119229; -.
DR   HOGENOM; HOG000041175; -.
DR   HOVERGEN; HBG006297; -.
DR   InParanoid; P10253; -.
DR   KO; K12316; -.
DR   OMA; SSEMGYT; -.
DR   OrthoDB; EOG091G030L; -.
DR   PhylomeDB; P10253; -.
DR   TreeFam; TF314577; -.
DR   BRENDA; 3.2.1.20; 2681.
DR   Reactome; R-HSA-5357572; Lysosomal glycogen catabolism.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   GeneWiki; Acid_alpha-glucosidase; -.
DR   GenomeRNAi; 2548; -.
DR   PRO; PR:P10253; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000171298; -.
DR   CleanEx; HS_GAA; -.
DR   ExpressionAtlas; P10253; baseline and differential.
DR   Genevisible; P10253; HS.
DR   GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0004558; F:alpha-1,4-glucosidase activity; IDA:BHF-UCL.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:InterPro.
DR   GO; GO:0032450; F:maltose alpha-glucosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004574; F:oligo-1,6-glucosidase activity; EXP:Reactome.
DR   GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0002086; P:diaphragm contraction; IMP:BHF-UCL.
DR   GO; GO:0006006; P:glucose metabolic process; IC:BHF-UCL.
DR   GO; GO:0005980; P:glycogen catabolic process; IDA:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007040; P:lysosome organization; IMP:BHF-UCL.
DR   GO; GO:0000023; P:maltose metabolic process; IC:BHF-UCL.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0050884; P:neuromuscular process controlling posture; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IEA:Ensembl.
DR   GO; GO:0005985; P:sucrose metabolic process; IC:BHF-UCL.
DR   GO; GO:0009888; P:tissue development; IEA:Ensembl.
DR   GO; GO:0043181; P:vacuolar sequestering; IMP:BHF-UCL.
DR   CDD; cd00111; Trefoil; 1.
DR   InterPro; IPR031727; Gal_mutarotase_N.
DR   InterPro; IPR011013; Gal_mutarotase_SF_dom.
DR   InterPro; IPR000322; Glyco_hydro_31.
DR   InterPro; IPR030458; Glyco_hydro_31_AS.
DR   InterPro; IPR030459; Glyco_hydro_31_CS.
DR   InterPro; IPR025887; Glyco_hydro_31_N_dom.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR017957; P_trefoil_CS.
DR   InterPro; IPR000519; P_trefoil_dom.
DR   Pfam; PF13802; Gal_mutarotas_2; 1.
DR   Pfam; PF01055; Glyco_hydro_31; 1.
DR   Pfam; PF16863; NtCtMGAM_N; 1.
DR   Pfam; PF00088; Trefoil; 1.
DR   SMART; SM00018; PD; 1.
DR   SUPFAM; SSF51445; SSF51445; 2.
DR   SUPFAM; SSF74650; SSF74650; 1.
DR   PROSITE; PS00129; GLYCOSYL_HYDROL_F31_1; 1.
DR   PROSITE; PS00707; GLYCOSYL_HYDROL_F31_2; 1.
DR   PROSITE; PS00025; P_TREFOIL_1; 1.
DR   PROSITE; PS51448; P_TREFOIL_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycogen storage disease; Glycoprotein; Glycosidase;
KW   Hydrolase; Lysosome; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Signal.
FT   SIGNAL        1     27       {ECO:0000255}.
FT   PROPEP       28     69       {ECO:0000269|PubMed:3049072}.
FT                                /FTId=PRO_0000018565.
FT   CHAIN        70    952       Lysosomal alpha-glucosidase.
FT                                /FTId=PRO_0000018566.
FT   CHAIN       123    952       76 kDa lysosomal alpha-glucosidase.
FT                                /FTId=PRO_0000018567.
FT   CHAIN       204    952       70 kDa lysosomal alpha-glucosidase.
FT                                /FTId=PRO_0000018568.
FT   DOMAIN       80    131       P-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00779}.
FT   ACT_SITE    518    518       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10066,
FT                                ECO:0000269|PubMed:1856189}.
FT   ACT_SITE    521    521       {ECO:0000250}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    233    233       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    390    390       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    470    470       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    652    652       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    882    882       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    925    925       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8435067}.
FT   DISULFID     82    109       {ECO:0000255|PROSITE-ProRule:PRU00779}.
FT   DISULFID     92    108       {ECO:0000255|PROSITE-ProRule:PRU00779}.
FT   DISULFID    103    127       {ECO:0000255|PROSITE-ProRule:PRU00779}.
FT   VARIANT      46     46       S -> P (in GSD2; dbSNP:rs777215354).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068564.
FT   VARIANT      74     74       R -> H (in dbSNP:rs764797280).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068565.
FT   VARIANT      89     89       R -> H (in dbSNP:rs200586324).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068566.
FT   VARIANT      91     91       D -> N (in allele GAA*2; lower affinity
FT                                for glycogen and starch but not for
FT                                lower-molecular weight substrates;
FT                                dbSNP:rs1800299).
FT                                {ECO:0000269|PubMed:21109266,
FT                                ECO:0000269|PubMed:2203258,
FT                                ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:9521422}.
FT                                /FTId=VAR_004285.
FT   VARIANT     103    103       C -> G (in GSD2; infantile form; severe;
FT                                loss of activity; shows enzyme
FT                                localization primarily in the ER-Golgi
FT                                compartment suggesting that mutation
FT                                could affect the normal processing and
FT                                stability of the enzyme;
FT                                dbSNP:rs398123174).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:21109266}.
FT                                /FTId=VAR_018078.
FT   VARIANT     103    103       C -> R (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068567.
FT   VARIANT     108    108       C -> G (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068568.
FT   VARIANT     127    127       C -> F (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068569.
FT   VARIANT     190    190       R -> H (in GSD2; dbSNP:rs528367092).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068570.
FT   VARIANT     191    191       Y -> C (in GSD2; extremely low residual
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046467.
FT   VARIANT     199    199       H -> R (in dbSNP:rs1042393).
FT                                {ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:3049072,
FT                                ECO:0000269|PubMed:7717400,
FT                                ECO:0000269|PubMed:9521422,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_004286.
FT   VARIANT     208    208       L -> P (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_029025.
FT   VARIANT     217    217       P -> L (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068571.
FT   VARIANT     219    219       G -> R (in GSD2; infantile form; severe;
FT                                loss of activity; dbSNP:rs370950728).
FT                                {ECO:0000269|PubMed:11738358,
FT                                ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_018079.
FT   VARIANT     220    220       V -> L (in dbSNP:rs530478036).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068572.
FT   VARIANT     222    222       V -> M (in dbSNP:rs374569672).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068573.
FT   VARIANT     223    223       R -> H (in dbSNP:rs1042395).
FT                                {ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:3049072,
FT                                ECO:0000269|PubMed:7717400,
FT                                ECO:0000269|PubMed:9521422,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_004287.
FT   VARIANT     224    224       R -> P (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068574.
FT   VARIANT     224    224       R -> Q (in GSD2; dbSNP:rs200210219).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068575.
FT   VARIANT     224    224       R -> W (in GSD2; infantile; mild partial
FT                                loss of activity; dbSNP:rs757700700).
FT                                {ECO:0000269|PubMed:12923862,
FT                                ECO:0000269|PubMed:14643388,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_029026.
FT   VARIANT     234    234       T -> K (in GSD2).
FT                                {ECO:0000269|PubMed:22644586,
FT                                ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_068576.
FT   VARIANT     234    234       T -> R (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068577.
FT   VARIANT     237    237       A -> V (in GSD2; dbSNP:rs121907944).
FT                                {ECO:0000269|PubMed:15668445}.
FT                                /FTId=VAR_029027.
FT   VARIANT     251    251       S -> L (in GSD2; dbSNP:rs200856561).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068578.
FT   VARIANT     254    254       S -> L (in GSD2; dbSNP:rs577915581).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068579.
FT   VARIANT     262    262       E -> K (in GSD2; infantile; severe;
FT                                dbSNP:rs201896815).
FT                                {ECO:0000269|PubMed:11738358,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_029028.
FT   VARIANT     266    266       P -> S (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068580.
FT   VARIANT     271    271       T -> A. {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068581.
FT   VARIANT     285    285       P -> R (in GSD2; juvenile form; mild;
FT                                partial loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018080.
FT   VARIANT     285    285       P -> S (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068582.
FT   VARIANT     290    290       N -> D (in dbSNP:rs552929702).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068583.
FT   VARIANT     291    291       L -> F (in GSD2; dbSNP:rs773417785).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068584.
FT   VARIANT     291    291       L -> P (in GSD2).
FT                                {ECO:0000269|PubMed:18425781,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068585.
FT   VARIANT     292    292       Y -> C (in GSD2; juvenile form; mild;
FT                                partial loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018081.
FT   VARIANT     293    293       G -> R (in GSD2; infantile form; severe;
FT                                almost complete loss of activity;
FT                                dbSNP:rs121907945).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:15668445,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_018082.
FT   VARIANT     299    299       L -> R (in GSD2; infantile form;
FT                                dbSNP:rs121907940).
FT                                {ECO:0000269|PubMed:7717400}.
FT                                /FTId=VAR_004288.
FT   VARIANT     308    308       H -> L (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_046468.
FT   VARIANT     308    308       H -> P (in GSD2; infantile form; severe;
FT                                complete loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018083.
FT   VARIANT     309    309       G -> R (in GSD2; severe;
FT                                dbSNP:rs543300039).
FT                                {ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:9660056}.
FT                                /FTId=VAR_018084.
FT   VARIANT     310    310       V -> G (found in a patient with GSD2;
FT                                unknown pathological significance;
FT                                dbSNP:rs763091901).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068586.
FT   VARIANT     312    312       L -> R (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018085.
FT   VARIANT     316    316       N -> I (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068587.
FT   VARIANT     318    318       M -> K (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068588.
FT   VARIANT     318    318       M -> T (in GSD2; severe;
FT                                dbSNP:rs121907936).
FT                                {ECO:0000269|PubMed:1652892}.
FT                                /FTId=VAR_004289.
FT   VARIANT     324    324       P -> L (in GSD2; dbSNP:rs750030887).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_029029.
FT   VARIANT     330    330       W -> G (in GSD2; infantile form; severe).
FT                                {ECO:0000269|PubMed:16782080}.
FT                                /FTId=VAR_029030.
FT   VARIANT     335    335       G -> E (in GSD2; dbSNP:rs730880022).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068589.
FT   VARIANT     335    335       G -> R (in GSD2; dbSNP:rs202095215).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068590.
FT   VARIANT     347    347       P -> R (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068591.
FT   VARIANT     355    355       L -> P (in GSD2; infantile form; severe;
FT                                loss of activity; dbSNP:rs766074609).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:14972326,
FT                                ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:17643989,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_018086.
FT   VARIANT     359    359       G -> R. {ECO:0000269|PubMed:17643989}.
FT                                /FTId=VAR_068592.
FT   VARIANT     361    361       P -> L (in GSD2; juvenile form; severe;
FT                                dbSNP:rs755253527).
FT                                {ECO:0000269|PubMed:12601120,
FT                                ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_029031.
FT   VARIANT     374    374       C -> R (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018087.
FT   VARIANT     375    375       R -> L (in GSD2; extremely low residual
FT                                enzymatic activity; dbSNP:rs142752477).
FT                                {ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046469.
FT   VARIANT     377    377       G -> R (in GSD2; severe;
FT                                dbSNP:rs752002666).
FT                                /FTId=VAR_029032.
FT   VARIANT     391    391       M -> V (found in a patient with GSD2;
FT                                unknown pathological significance;
FT                                dbSNP:rs778634337).
FT                                {ECO:0000269|PubMed:22644586,
FT                                ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_068593.
FT   VARIANT     397    397       P -> L (in GSD2; dbSNP:rs776008078).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068594.
FT   VARIANT     401    401       Q -> R (in GSD2; extremely low residual
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046470.
FT   VARIANT     402    402       W -> R (in GSD2; severe).
FT                                /FTId=VAR_004290.
FT   VARIANT     404    404       D -> N (in GSD2; severe;
FT                                dbSNP:rs141533320).
FT                                /FTId=VAR_029033.
FT   VARIANT     405    405       L -> P (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018088.
FT   VARIANT     408    408       M -> V (in GSD2; juvenile form; severe;
FT                                dbSNP:rs560575383).
FT                                {ECO:0000269|PubMed:11738358,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_029034.
FT   VARIANT     419    419       D -> V (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068595.
FT   VARIANT     431    433       Missing (in GSD2).
FT                                {ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_070017.
FT   VARIANT     437    437       R -> C (in GSD2; juvenile form; severe;
FT                                dbSNP:rs770610356).
FT                                {ECO:0000269|PubMed:12601120}.
FT                                /FTId=VAR_029035.
FT   VARIANT     437    437       R -> H (in GSD2; unknown pathological
FT                                significance; dbSNP:rs150868652).
FT                                {ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_074277.
FT   VARIANT     445    445       A -> P (in GSD2).
FT                                {ECO:0000269|PubMed:16917947}.
FT                                /FTId=VAR_029036.
FT   VARIANT     455    455       Y -> F (in GSD2; juvenile form; almost
FT                                complete loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018089.
FT   VARIANT     457    457       P -> H (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068596.
FT   VARIANT     457    457       P -> L (in GSD2; juvenile form).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_029040.
FT   VARIANT     458    458       Y -> C. {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068597.
FT   VARIANT     459    459       Missing (in GSD2; infantile form;
FT                                severe). {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018090.
FT   VARIANT     478    478       G -> R (in GSD2; severe; loss of
FT                                activity; dbSNP:rs778068209).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_004291.
FT   VARIANT     481    481       W -> R (in GSD2; severe; loss of
FT                                activity; dbSNP:rs772883420).
FT                                {ECO:0000269|PubMed:10189220,
FT                                ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_004292.
FT   VARIANT     482    482       P -> R (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068598.
FT   VARIANT     483    483       G -> V (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068599.
FT   VARIANT     486    486       A -> P (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068600.
FT   VARIANT     489    489       D -> N (in GSD2; severe;
FT                                dbSNP:rs398123169).
FT                                {ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_029037.
FT   VARIANT     519    519       M -> T (in GSD2; severe; loss of
FT                                activity; dbSNP:rs786204720).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_004293.
FT   VARIANT     519    519       M -> V (in GSD2).
FT                                {ECO:0000269|PubMed:7866409}.
FT                                /FTId=VAR_004294.
FT   VARIANT     521    521       E -> K (in GSD2; severe;
FT                                dbSNP:rs121907937).
FT                                {ECO:0000269|PubMed:1898413}.
FT                                /FTId=VAR_004295.
FT   VARIANT     521    521       E -> Q (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068601.
FT   VARIANT     522    522       P -> A (in GSD2; no residual enzymatic
FT                                activity). {ECO:0000269|PubMed:17643989,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046471.
FT   VARIANT     522    522       P -> S (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068602.
FT   VARIANT     523    523       S -> Y (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068603.
FT   VARIANT     525    525       F -> Y (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068604.
FT   VARIANT     529    529       S -> V (in GSD2; mild; requires 2
FT                                nucleotide substitutions;
FT                                dbSNP:rs121907941).
FT                                {ECO:0000269|PubMed:8834250}.
FT                                /FTId=VAR_004296.
FT   VARIANT     545    545       P -> L (in GSD2; mild; partial loss of
FT                                activity; dbSNP:rs121907942).
FT                                {ECO:0000269|PubMed:10737124,
FT                                ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:20080426,
FT                                ECO:0000269|PubMed:7881422}.
FT                                /FTId=VAR_004297.
FT   VARIANT     549    549       G -> R (in GSD2; juvenile form; mild;
FT                                partial loss of activity).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:16917947}.
FT                                /FTId=VAR_018091.
FT   VARIANT     552    552       L -> P (in GSD2; infantile/juvenile form;
FT                                severe; loss of activity;
FT                                dbSNP:rs779556619).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_018092.
FT   VARIANT     557    557       I -> F (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068605.
FT   VARIANT     558    558       C -> S (in GSD2).
FT                                {ECO:0000269|PubMed:20350966,
FT                                ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068606.
FT   VARIANT     566    566       S -> P (in GSD2; infantile form).
FT                                {ECO:0000269|PubMed:9521422}.
FT                                /FTId=VAR_004298.
FT   VARIANT     568    568       H -> L (in GSD2).
FT                                {ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_070018.
FT   VARIANT     570    570       N -> K (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068607.
FT   VARIANT     572    572       H -> Q (in GSD2; dbSNP:rs772962666).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068608.
FT   VARIANT     575    575       Y -> C (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068609.
FT   VARIANT     575    575       Y -> S (in GSD2; juvenile form).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018093.
FT   VARIANT     576    576       G -> A.
FT                                /FTId=VAR_004299.
FT   VARIANT     576    576       G -> R (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068610.
FT   VARIANT     576    576       G -> S (retains about half of the
FT                                activity compared with the wild-type;
FT                                dbSNP:rs1800307).
FT                                {ECO:0000269|PubMed:14643388,
FT                                ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_004300.
FT   VARIANT     579    579       E -> K (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018094.
FT   VARIANT     585    585       R -> K (in dbSNP:rs747373179).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068611.
FT   VARIANT     585    585       R -> M (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_046472.
FT   VARIANT     594    594       R -> H (in GSD2; dbSNP:rs775450536).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068612.
FT   VARIANT     594    594       R -> P (in GSD2; dbSNP:rs775450536).
FT                                {ECO:0000269|PubMed:18425781,
FT                                ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068613.
FT   VARIANT     599    599       S -> Y (in GSD2; no residual enzymatic
FT                                activity; dbSNP:rs753505203).
FT                                {ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046473.
FT   VARIANT     600    600       R -> C (in GSD2; juvenile form; loss of
FT                                activity; dbSNP:rs764670084).
FT                                {ECO:0000269|PubMed:14643388,
FT                                ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018095.
FT   VARIANT     600    600       R -> H (in GSD2; infantile form;
FT                                dbSNP:rs377544304).
FT                                /FTId=VAR_008689.
FT   VARIANT     601    601       S -> L (in GSD2).
FT                                {ECO:0000269|PubMed:22644586,
FT                                ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_068614.
FT   VARIANT     602    602       T -> A (in GSD2; dbSNP:rs781484283).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068615.
FT   VARIANT     607    612       Missing (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_046474.
FT   VARIANT     607    607       G -> D (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018096.
FT   VARIANT     610    610       A -> V (in GSD2).
FT                                {ECO:0000269|PubMed:17643989}.
FT                                /FTId=VAR_068616.
FT   VARIANT     611    611       G -> D (found in a patient with GSD2;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:22644586,
FT                                ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_068617.
FT   VARIANT     612    612       H -> Q (in GSD2).
FT                                {ECO:0000269|PubMed:16917947}.
FT                                /FTId=VAR_029038.
FT   VARIANT     612    612       H -> Y (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068618.
FT   VARIANT     614    614       T -> K (in GSD2; dbSNP:rs369531647).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068619.
FT   VARIANT     615    615       G -> R (in GSD2; infantile/adult form;
FT                                dbSNP:rs549029029).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_008690.
FT   VARIANT     619    619       S -> R (in GSD2; loss of function of the
FT                                mutant enzyme).
FT                                {ECO:0000269|PubMed:14643388}.
FT                                /FTId=VAR_046475.
FT   VARIANT     627    627       S -> P (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068620.
FT   VARIANT     629    629       P -> L (in dbSNP:rs746961289).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068621.
FT   VARIANT     635    635       N -> K (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068622.
FT   VARIANT     638    638       G -> V (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068623.
FT   VARIANT     638    638       G -> W (in GSD2; dbSNP:rs757617999).
FT                                {ECO:0000269|PubMed:10737124,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046476.
FT   VARIANT     641    641       L -> V (in GSD2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_074278.
FT   VARIANT     643    643       G -> R (in GSD2; infantile form;
FT                                dbSNP:rs28937909).
FT                                {ECO:0000269|PubMed:11071489,
FT                                ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:8401535,
FT                                ECO:0000269|PubMed:9521422}.
FT                                /FTId=VAR_004301.
FT   VARIANT     645    645       D -> E (in GSD2; infantile form; most
FT                                common mutation; deficient in
FT                                phosphorylation and in proteolytic
FT                                processing; dbSNP:rs28940868).
FT                                {ECO:0000269|PubMed:1684505,
FT                                ECO:0000269|PubMed:20080426,
FT                                ECO:0000269|PubMed:8094613}.
FT                                /FTId=VAR_004302.
FT   VARIANT     645    645       D -> H (in GSD2; almost complete loss of
FT                                activity; dbSNP:rs368438393).
FT                                {ECO:0000269|PubMed:7695647}.
FT                                /FTId=VAR_004303.
FT   VARIANT     645    645       D -> N (in GSD2; dbSNP:rs368438393).
FT                                {ECO:0000269|PubMed:15145338,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004304.
FT   VARIANT     647    647       C -> W (in GSD2; dbSNP:rs776948121).
FT                                {ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:7981676,
FT                                ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004305.
FT   VARIANT     648    648       G -> D (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068624.
FT   VARIANT     648    648       G -> S (in GSD2; dbSNP:rs536906561).
FT                                {ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004306.
FT   VARIANT     660    660       R -> H (in GSD2; loss of function of the
FT                                mutant enzyme; dbSNP:rs374143224).
FT                                {ECO:0000269|PubMed:14643388}.
FT                                /FTId=VAR_046477.
FT   VARIANT     672    672       R -> Q (in GSD2; dbSNP:rs778418246).
FT                                {ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004307.
FT   VARIANT     672    672       R -> T (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_046478.
FT   VARIANT     672    672       R -> W (in GSD2; dbSNP:rs757111744).
FT                                {ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004308.
FT   VARIANT     675    675       Missing (in GSD2; infantile form).
FT                                /FTId=VAR_008692.
FT   VARIANT     689    689       E -> K (in allele GAA*4;
FT                                dbSNP:rs1800309).
FT                                {ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:8912788}.
FT                                /FTId=VAR_004309.
FT   VARIANT     700    701       Missing (found in a patient with GSD2;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068625.
FT   VARIANT     702    702       R -> C (in GSD2; no enzymatic activity;
FT                                shows enzyme localization primarily in
FT                                the ER-Golgi compartment suggesting that
FT                                mutation could affect the normal
FT                                processing and stability of the enzyme;
FT                                dbSNP:rs786204645).
FT                                {ECO:0000269|PubMed:14972326}.
FT                                /FTId=VAR_046479.
FT   VARIANT     702    702       R -> L (in GSD2; dbSNP:rs398123172).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068626.
FT   VARIANT     705    705       L -> P (in GSD2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_074279.
FT   VARIANT     711    711       T -> R (in dbSNP:rs759292700).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068627.
FT   VARIANT     718    718       V -> I (in dbSNP:rs141017311).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068628.
FT   VARIANT     725    725       R -> W (in GSD2; adult form;
FT                                dbSNP:rs28939100).
FT                                {ECO:0000269|PubMed:8401535}.
FT                                /FTId=VAR_004310.
FT   VARIANT     737    737       T -> N (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068629.
FT   VARIANT     743    743       Q -> K (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068630.
FT   VARIANT     746    746       W -> C (in dbSNP:rs1800312).
FT                                {ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_004311.
FT   VARIANT     746    746       W -> G (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068631.
FT   VARIANT     746    746       W -> S (in GSD2; dbSNP:rs752921215).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068632.
FT   VARIANT     766    766       Y -> C (in GSD2; dbSNP:rs144016984).
FT                                {ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_070019.
FT   VARIANT     768    768       P -> R (in GSD2; infantile form).
FT                                {ECO:0000269|PubMed:9521422}.
FT                                /FTId=VAR_004312.
FT   VARIANT     780    780       V -> I (in dbSNP:rs1126690).
FT                                {ECO:0000269|PubMed:2111708,
FT                                ECO:0000269|PubMed:2268276,
FT                                ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:3049072,
FT                                ECO:0000269|PubMed:7717400,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_004313.
FT   VARIANT     816    816       V -> I (in dbSNP:rs1800314).
FT                                {ECO:0000269|PubMed:1684505,
FT                                ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:8094613,
FT                                ECO:0000269|PubMed:8486380}.
FT                                /FTId=VAR_004314.
FT   VARIANT     819    819       R -> P (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068633.
FT   VARIANT     880    880       A -> D (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018097.
FT   VARIANT     901    901       L -> Q (in GSD2; infantile form; severe).
FT                                {ECO:0000269|PubMed:15145338}.
FT                                /FTId=VAR_029039.
FT   VARIANT     903    903       Missing (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:7717400}.
FT                                /FTId=VAR_004315.
FT   VARIANT     913    913       P -> R (in GSD2).
FT                                {ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_070020.
FT   VARIANT     916    916       V -> F (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068634.
FT   VARIANT     925    925       N -> NGVPVSN (in GSD2).
FT                                {ECO:0000269|PubMed:10206684}.
FT                                /FTId=VAR_004316.
FT   VARIANT     927    927       T -> I (loss of glycosylation site;
FT                                dbSNP:rs1800315).
FT                                {ECO:0000269|PubMed:1684505,
FT                                ECO:0000269|PubMed:8094613,
FT                                ECO:0000269|PubMed:8486380}.
FT                                /FTId=VAR_004317.
FT   VARIANT     935    935       L -> P (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068635.
FT   VARIANT     949    949       V -> D (in GSD2).
FT                                /FTId=VAR_004318.
FT   MUTAGEN     516    516       W->R: Loss of activity.
FT                                {ECO:0000269|PubMed:1856189}.
FT   MUTAGEN     518    518       D->G,N,E: Loss of activity.
FT                                {ECO:0000269|PubMed:1856189}.
SQ   SEQUENCE   952 AA;  105324 MW;  6E2717BF7201F469 CRC64;
     MGVRHPPCSH RLLAVCALVS LATAALLGHI LLHDFLLVPR ELSGSSPVLE ETHPAHQQGA
     SRPGPRDAQA HPGRPRAVPT QCDVPPNSRF DCAPDKAITQ EQCEARGCCY IPAKQGLQGA
     QMGQPWCFFP PSYPSYKLEN LSSSEMGYTA TLTRTTPTFF PKDILTLRLD VMMETENRLH
     FTIKDPANRR YEVPLETPHV HSRAPSPLYS VEFSEEPFGV IVRRQLDGRV LLNTTVAPLF
     FADQFLQLST SLPSQYITGL AEHLSPLMLS TSWTRITLWN RDLAPTPGAN LYGSHPFYLA
     LEDGGSAHGV FLLNSNAMDV VLQPSPALSW RSTGGILDVY IFLGPEPKSV VQQYLDVVGY
     PFMPPYWGLG FHLCRWGYSS TAITRQVVEN MTRAHFPLDV QWNDLDYMDS RRDFTFNKDG
     FRDFPAMVQE LHQGGRRYMM IVDPAISSSG PAGSYRPYDE GLRRGVFITN ETGQPLIGKV
     WPGSTAFPDF TNPTALAWWE DMVAEFHDQV PFDGMWIDMN EPSNFIRGSE DGCPNNELEN
     PPYVPGVVGG TLQAATICAS SHQFLSTHYN LHNLYGLTEA IASHRALVKA RGTRPFVISR
     STFAGHGRYA GHWTGDVWSS WEQLASSVPE ILQFNLLGVP LVGADVCGFL GNTSEELCVR
     WTQLGAFYPF MRNHNSLLSL PQEPYSFSEP AQQAMRKALT LRYALLPHLY TLFHQAHVAG
     ETVARPLFLE FPKDSSTWTV DHQLLWGEAL LITPVLQAGK AEVTGYFPLG TWYDLQTVPV
     EALGSLPPPP AAPREPAIHS EGQWVTLPAP LDTINVHLRA GYIIPLQGPG LTTTESRQQP
     MALAVALTKG GEARGELFWD DGESLEVLER GAYTQVIFLA RNNTIVNELV RVTSEGAGLQ
     LQKVTVLGVA TAPQQVLSNG VPVSNFTYSP DTKVLDICVS LLMGEQFLVS WC
//
